Zhende Medical Co (603301) Fair Value & Analysis
Healthcare · CN · Market cap 22.5B CNY
Fair value as of: Aug 10, 2026
From 17 valuation models · updated today
Share price −5.0% over the past month.
A solid business, but screening 75% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥27.18). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 10, 2026.
How to read this chart
60‑month range ¥16.89 – ¥100.22 · fair‑value band ¥16.31 – ¥27.18 · the ¥85.32 price screens above the ¥21.74 fair value. Dashed = 300-day average. As of Aug 10, 2026.
Analysis
Zhende Medical Co (603301) currently trades at ¥85.32, while our model-based Fair Value estimate is ¥21.74, implying the stock looks roughly 74.5% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Zhende Medical Co generated revenue of 4.3B CNY at a net margin of 6.1%. Revenue grew 0.9% year over year. It earns a return on equity of 4.6%. Net debt stands at 325M CNY. Fundamentals as of Aug 10, 2026
Our scenario range runs from ¥16.31 (bear case) to ¥27.18 (bull case); at ¥85.32, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 19% below its 52-week high and 331% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -75%, 603301 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 17 models by family
Widest divergence: Growth Earnings (¥25.14) versus DCF Models (¥2.62). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 10, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 71
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhende Medical Co., Ltd. engages in the research and development, production, and sale of medical care and protective equipment in China and internationally.
Full company description
Zhende Medical Co., Ltd. engages in the research and development, production, and sale of medical care and protective equipment in China and internationally. The company offers gauze swab, lap sponge, and fluff gauze swab; non-woven swab; PBT bandage, elastic bandage, crepe bandage, crochet bandage, selvedge bandage, under-cast padding, and fluff gauze roll; dressing set; first aid kit; cotton pad and applicator; and gauze roll and abdominal pad. It also provides surgical gown, scrub suit, warm-up jacket, surgical headwear, and isolation gown; Surgical drape; standard surgical pack and custom procedure pack; equipment cover; OP Tape, hand towel, and fluid collection pouch; latex surgical glove; CSR wrap; and warming blanket system. In addition, the company offers isolation gown, surgical cap, shoe cover, medical mask, and particular respirator; compression bandage and compression stocking; wound care products; pre-filled flush syringes; and ostomy and accessories. Further, it provides respiratory health, home cleaning, IP collaboration, nasal care, protective gear and assistive devices, and personal beauty products. Zhende Medical Co., Ltd. was incorporated in 1994 and is headquartered in Shaoxing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhende Medical Co reported revenue of ¥4.3B in FY2025 versus ¥5.1B in FY2021, a compound −4.0%/yr. Reported net income was ¥261M in FY2025, compounding −18.7%/yr from FY2021.
603301 screens 75% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 10, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Zhende Medical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Zhende Medical Co (603301) overvalued or undervalued?
What is the fair value of 603301?
What is the quality score of 603301?
What is the revenue of Zhende Medical Co (603301)?
What is the net profit margin of 603301?
Does Zhende Medical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhende Medical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.